Our friend @bingbingbom is banned for no obvious reason.

RT @meremrtl: $OMER

x.com/meremrtl/status/206359… Line up the BBC puts on every bounce

RT @TSawyer84: $ABVX

BREAKING: ETH just dropped its new logo

Fellas, looking for advice. My girlfriend's Google Business Profile is attacker by local competitor. They hire someone who controls a 3rd party location, and change the name address of that location to match ours. This causes Google to automerge their business into ours and we lost access to our business on Google Maps. Google Support had been completely useless and did not help us at all. Should we retaliate against our competitor? We have no option at this point.

$ABVX has developed the greatest ulcerative colitis drug of all time. Time to start pricing in Crohn’s.

Nice ones! Godspeed Ukraine! "The Russians entered this war under the rather childish delusion that they were going to bomb everybody, and nobody was going to bomb them."

One of the BEST ways to know that you're in a bubble is when people persistently claim that we can't possibly be in a bubble!

I am so sick of actors giving us their dogshit opinions on things. Shut up, read the script and fuck off.

Who else does this

$PSNL had posted quite a number of openings recently, including (among many) 3 commercialization executives & 2 MSLs. Seems like they are ready to ramp up commercialization What caught my eyes is, they are also hiring quite a large number of lab-based staffs, many of them in the evening/night shifts. Looks like they need the team to section/macrodissect tumors and run the NGS 24/7 to meet demand I know this isn't uncommon in the biotech space, but may imply on the demand of their MRD tests now after they received 2 Medicare coverages. Their Q2 results should be interesting

the 1 thing this $INTC trade should teach you is fundamentals mean nothing when it comes to making money. P/E ratios lol. Names like $PYPL $ADBE, $FISV are dirt cheap and trade like shit, making money is easy but most of you are masochists, just buy what is being bought.

Anthropic said Mythos was too dangerous to release. Then four random guys in a Discord gained access on day one by guessing the URL... This is pretty insane: → Group in a private Discord guessed the endpoint from Anthropic's naming conventions → They figured out the conventions from the leak in the Mercor breach three weeks ago → Used a contractor's legit eval credentials to walk in → Have been using it ever since to build simple websites The AI that finds zero-days in every operating system on earth was defeated by address bar autocomplete... big yikes

$qure $clpt Sung is still backing amt 130 big time, look at some of the new quotes, at the AAN Annual Meeting The FDA recommends a large, sham, phase 3 trial to prove efficacy, and [drug manufacturer] uniQure is exploring all options to continue forward with AMT-130,” Dr. Sung said. “We don’t know official timelines yet, but we hope for updates soon.” “The results are in some ways better than what we hoped to see at this point,” said principal study author Victor Sung, MD, director of the University of Alabama at Birmingham’s Huntington's Disease Clinic. “We had previously reported no new safety events at the two-year follow-up mark, and it was not surprising that there were also no new safety events with this three-year follow-up. A pleasant surprise was the continued separation in all clinical measures of the high-dose treated group from the comparator group.” “Enroll-HD is a massive observational trial in HD with over 10 years of longitudinal data from over 60,000 persons with HD,” Dr. Sung said. “Only in a dataset that large could we find an appropriately tightly matched group to the AMT-130-treated subjects that does not feel cherry-picked to make AMT-130 look better.” The NfL data is compelling for the disease-modifying potential of AMT-130,” Dr. Sung said. “Certainly, it was included initially as a measure of safety, but the holding of NfL at or below baseline at the three-year mark is impressive in the context that NfL levels for all neurodegenerative diseases typically only increase with time.” neurologytoday.aan.com/doi/1… @DesertDweller93 @peter_mantas

"Melanoma doctors tell us the FDA’s rejection of RP1 makes no sense and will cost thousands of lives." This one is a head scratcher unless we're missing something. "“Lord knows I’ve given enough chemotherapy in my lifetime to melanoma patients to know how dismal that outcome is,” Dr. Pavlick says. Remarkably, a third of patients who failed to respond to a standard anti-PD-1 regimen went into remission with RP1. “I have patients who have been treated with this drug that are still alive today who would otherwise be dead,” she says. The FDA claimed the anti-PD-1 drug, not RP1, might have been the reason patients went into remission. That’s “ludicrous,” Dr. Pavlick says. “These are patients that hands down progressed on anti-PD-1.” She calls FDA’s demand for a control group “completely unethical” since “they’re progressing on that treatment”—that is, their cancer is getting worse." wsj.com/opinion/fda-rp1-repl… via @WSJopinion

I mean, come on guys 😅 $NKTR

$TARS valuation, analyst consensus & related multiples v actual M&A multiples paid to acquire $FOLD & $APLS Note TARS' revenues generate higher gross margins. Does that suggest TARS would warrant a higher multiple (all other things being equal)? $XBI $IBB $DVAX $SLNO $DAWN $PFE